Hydrogen Gas Inhalation Treatment for Coronary Artery Lesions in a Kawasaki Disease Mouse Model.
Wen-Ling Shih, Tsung-Ming Yeh, Kuang-Den Chen, Steve Leu, Shih-Feng Liu, Ying-Hsien Huang, Ho-Chang Kuo · Life (Basel, Switzerland) · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
The researchers observed significant dilatation and higher Z scores in the left coronary artery (LCA) in D21 and D28 in mice after LCWE treatment compared to the control group (p < 0.001) and a significant resolution of LCA diameters (p < 0.01) and Z scores (p < 0.01) after treatment with inhaled hydrogen gas. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in mice. The researchers observed significant dilatation and higher Z scores in the left coronary artery (LCA) in D21 and D28 in mice after LCWE treatment compared to the control group (p < 0.001) and a significant resolution of LCA diameters (p < 0.01) and Z scores (p < 0.01) after treatment with inhaled hydrogen gas.
What the Researchers Studied
The researchers studied mice. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Figure 1 shows a schematic diagram of the LCWE murine model of KD vasculitis and the therapeutics of inhaled hydrogen gas. The threshold for significance was set at p ≤ To gain insight into the possible involvement of inhaled hydrogen gas in preventing the development of CALs, the researchers used an LCWE-injected mouse model, which has been shown to induce CAL formation. The researchers observed significant dilatation and higher Z scores in the left coronary artery (LCA) in D21 and D28 in mice after LCWE treatment compared to the control group (p < 0.001) and a significant resolution of LCA diameters (p < 0.01) and Z scores (p < 0.01) after treatment with inhaled hydrogen gas. The authors concluded that according to the authors' literature review, this is the first report where hydrogen gas inhalation has been demonstrated to be effective for the treatment of coronary artery dilatation in a KD murine model. Hydrogen gas exhibits potent antioxidant properties that effectively regulate ROS production and the inflammatory response. the data indicate that inhaled hydrogen gas therapy reduces the LCWE-induced dilatation of LCA and inflammatory cytokine IL-6 expression.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was mice. The study used a preclinical animal experiment. The hydrogen delivery method was inhaled hydrogen gas.
Limitations and Safety
Safety information: Before conducting large-scale clinical trials in children with KD, it is necessary to assess the safety and efficacy of inhaled hydrogen gas in an animal model of KD, specifically LCWE-induced vasculitis.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.